Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: purified talc; pregelatinised maize starch; stearic acid; maize starch; povidone; potassium sorbate - relief of pain and discomfort in arthritis, headahce, muscular and neuralgic conditions. reduced fever. panamax is useful as an analgesic for patients with dyspepsia, ulcers or gout.

Singapore - English - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - ketorolac tromethamine - solution, sterile - 0.45% w/v - ketorolac tromethamine 0.45% w/v

United States - English - NLM (National Library of Medicine)

biocomp pharma, inc. - ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), ferrous gluconate (unii: u1b11i423z) (ferrous cation - unii:gw89581owr), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204) - ascorbic acid 138 mg - bioferr™ 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

United States - English - NLM (National Library of Medicine)

mission pharmacal company - iron (unii: e1uol152h7) (iron - unii:e1uol152h7), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag) - ferralet ® 90 is indicated for the treatment of all anemias that are responsive to oral iron therapy. these include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, postsurgical convalescence, and dietary needs. hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

الشركة المتحدة لصناعة الأدوية - united pharmaceutical manufacturing co. ltd. - ticagrelor 90.0 mg/1 tab - 90.0 mg/1 tab

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - codeine phosphate hemihydrate, quantity: 8 mg; paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: soluble maize starch; povidone; microcrystalline cellulose; stearic acid; potassium sorbate; magnesium stearate; maize starch; purified talc - for the relief of acute moderate pain

New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - sodium chloride 0.45% - irrigation - 0.45 % - active: sodium chloride 0.45%

United States - English - NLM (National Library of Medicine)

trigen laboratories, llc - docusate sodium (unii: f05q2t2ja0) (docusate - unii:m7p27195ag), folic acid (unii: 935e97boy8) (folic acid - unii:935e97boy8), iron pentacarbonyl (unii: 6wq62taq6z) (ferrous cation - unii:gw89581owr), cyanocobalamin (unii: p6yc3eg204) (cyanocobalamin - unii:p6yc3eg204), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r) - docusate sodium 50 mg - hypersensitivity to any of the ingredients. hemolytic anemia, hemochromatosis, and hemosiderosis are contraindications to iron therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - omega-3-acid ethyl esters 90, quantity: 1000 mg - capsule, soft - excipient ingredients: purified water; gelatin; glycerol; d-alpha-tocopherol - hypertriglyceridaemia: endogenous hypertriglyceridaemia as a supplement to diet when dietary measures alone are insufficient to produce an adequate response. treatment is indicated for the following types of dyslipidaemia (fredrickson classification) only: -type iv & v as monotherapy and with close monitoring of ldl-c levels. - type iib as add-on therapy to statins, when control of triglycerides with statins has been shown to be insufficient. patients with higher baseline levels of triglycerides are more likely to exhibit a better response to omacor. omacor is not indicated in exogenous hypertriglyceridaemia (type 1 hyperchylomicronaemia). there are insufficient data to support the use in patients with secondary endogenous hypertriglyceridaemia including patients with diabetes mellitus.

Philippines - English - FDA (Food And Drug Administration)

20170223094202 - singapore - medtronic philippines, inc. - medtronic philippines, inc.